Strategic Update: LEX Diagnostics has received FDA 510(k) clearance and CLIA waived status for its LEX VELO point of care molecular diagnostics system

LEX Diagnostics just secured FDA 510(k) clearance and CLIA‑waived status for its ultra‑fast VELO PCR system—another major milestone in the evolution of point‑of‑care molecular testing. The VELO platform delivers lab‑quality PCR results in just 6–10 minutes for Influenza A, Influenza B, and COVID‑19, with a cartridge‑based design that eliminates liquid handling and integrates seamlessly into urgent care, primary care, pharmacies, and decentralized acute settings. Clinical studies completed during the 2024/2025 respiratory season demonstrated strong performance, and U.S. commercial rollout is expected in 2026. This clearance also sets the stage for QuidelOrtho’s planned acquisition of LEX Diagnostics—another sign of accelerating consolidation and innovation in the POC molecular space. As platforms like VELO push PCR closer to the patient, the point‑of‑care market is entering a new phase defined by speed, sensitivity, and decentralized clinical decision‑making. GRN IVD Consulting: Point‑of‑Care Market Report For diagnostics manufacturers, investors, and health‑system leaders navigating this rapidly shifting landscape, the GRN IVD Consulting POC Market Report provides the clarity needed to stay ahead: ✔ Competitive intelligence across leading and emerging POC molecular platforms ✔ Technology and workflow comparisons that highlight true differentiation ✔ Regulatory and reimbursement tracking, including CLIA‑waived trends ✔ Market sizing, adoption drivers, and strategic positioning guidance ✔ Actionable recommendations for BD, portfolio strategy, and commercialization If you’re shaping the future of point‑of‑care diagnostics, this report gives you the strategic insight to move with confidence. Register and log in to receive a copy of the report.